|Day's Range||0.3000 - 0.3480|
|52 Week Range||0.2600 - 0.7200|
|PE Ratio (TTM)||-2.16|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
STELLENBOSCH, South Africa , July 25, 2017 /PRNewswire/ -- AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa ), announced that it has received grant status for the patent application: PRODUCTION ...
NEW YORK, July 24, 2017-- iBio, Inc., a leader in developing plant-based biopharmaceuticals, announced today that it has entered into a $16 million common stock purchase agreement with Lincoln Park Capital ...
Ibio Inc (NYSEMKT:IBIO) shares are rising fast in Wednesday’s trading session. "For this project, AzarGen's synthetic promoters are being tested with the objective of including the top performer in iBio's proprietary protein production vector," said Robert Erwin, ibio's President. Ibio develops drugs for a range of fibrotic diseases such as pulmonary fibrosis, while AzarGen is a biotechnology company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants.